Abstract A024: CD3ζ ITAM diversity determines chimeric antigen receptor force and function

Abstract The Chimeric antigen receptor (CAR) T cell therapy is a powerful treatment for hematologic malignancies; however, clinical responses vary depending on CAR T cell function and persistence. The optimization of CAR design has gained considerable interest with a new focus on calibrating CAR intracellular signals via the immunoreceptor tyrosine-based activation motifs (ITAMs) to increase the fitness of CAR T cells. Evidence suggests that unique ITAM motifs at positions 1, 2, or 3 (ITAMs-A, B, and C respectively) of the CD3ζ signaling domain may have non-redundant roles in signal strength, T cell functionality, persistence, and memory formation. However, the individual contributions of each CD3ζ ITAM in transmitting force and activating mechanosensitive signals are yet unexplored. We have found that human CARs expressing specific ITAM sequences (ITAM-A, ITAM-B, or ITAM-C only) generate differing amounts of force and bond lifetimes after interacting with their target antigen, CD19. Therefore, a CAR may act as a mechanosensor similar to a TCR, discriminating the quality of the interaction with antigen as cellular-derived forces are applied to the bond. The higher transmission of force directly correlates with better anti-tumor efficacy in vitro and in vivo. Hence, understanding the mechanotransduction in CARs has important implications in “tuning” the activation of a CAR T cell without changing specificity. Citation Format: Hilda Echelibe, Shubhabrata Majumdar, Elizabeth Kolawole, Baoyu Liu, Maria Bettini, Brian Evavold, Matt Bettini. CD3ζ ITAM diversity determines chimeric antigen receptor force and function [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr A024.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Research
Published
2025-02-23
DOI
https://doi.org/10.1158/2326-6074.io2025-a024
Primary Topic
Immunotherapy and Immune Responses
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Abstract A024: CD3ζ ITAM diversity determines chimeric antigen receptor force and function

Hilda Echelibe, Matt Bettini, Baoyu Liu, Elizabeth Motunrayo Kolawole et al.
Cancer Immunology Research
Immunotherapy and Immune Responses
article

Abstract A024: CD3ζ ITAM diversity determines chimeric antigen receptor force and function

Hilda Echelibe, Matt Bettini, Baoyu Liu, Elizabeth Motunrayo Kolawole, Brian D. Evavold, Shubhabrata Majumdar, Maria Bettini
article en

Abstract

Abstract The Chimeric antigen receptor (CAR) T cell therapy is a powerful treatment for hematologic malignancies; however, clinical responses vary depending on CAR T cell function and persistence. The optimization of CAR design has gained considerable interest with a new focus on calibrating CAR intracellular signals via the immunoreceptor tyrosine-based activation motifs (ITAMs) to increase the fitness of CAR T cells. Evidence suggests that unique ITAM motifs at positions 1, 2, or 3 (ITAMs-A, B, and C respectively) of the CD3ζ signaling domain may have non-redundant roles in signal strength, T cell functionality, persistence, and memory formation. However, the individual contributions of each CD3ζ ITAM in transmitting force and activating mechanosensitive signals are yet unexplored. We have found that human CARs expressing specific ITAM sequences (ITAM-A, ITAM-B, or ITAM-C only) generate differing amounts of force and bond lifetimes after interacting with their target antigen, CD19. Therefore, a CAR may act as a mechanosensor similar to a TCR, discriminating the quality of the interaction with antigen as cellular-derived forces are applied to the bond. The higher transmission of force directly correlates with better anti-tumor efficacy in vitro and in vivo. Hence, understanding the mechanotransduction in CARs has important implications in “tuning” the activation of a CAR T cell without changing specificity. Citation Format: Hilda Echelibe, Shubhabrata Majumdar, Elizabeth Kolawole, Baoyu Liu, Maria Bettini, Brian Evavold, Matt Bettini. CD3ζ ITAM diversity determines chimeric antigen receptor force and function [abstract]. In: Proceedings of the AACR IO Conference: Discovery and Innovation in Cancer Immunology: Revolutionizing Treatment through Immunotherapy; 2025 Feb 23-26; Los Angeles, CA. Philadelphia (PA): AACR; Cancer Immunol Res 2025;13(2 Suppl):Abstract nr A024.

Cancer Immunology ResearchVol. 13(2_Supplement)
Baylor College of Medicine (US), University of Utah (US)
Openalex Percentile: Top 96%
Immunotherapy and Immune Responses
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.